2022
Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo
Bini J, Carson R, Cline G. Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo. Methods In Molecular Biology 2022, 2592: 61-74. PMID: 36507985, DOI: 10.1007/978-1-0716-2807-2_4.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 2DopamineHumansPositron-Emission TomographyReceptors, Dopamine D2Receptors, Dopamine D3TetrabenazineVesicular Monoamine Transport ProteinsConceptsPositron emission tomographyBeta-cell massFunctional beta-cell massDopamine D2/D3 receptorsD2/D3 receptorsBeta-cell lossType 2 diabetesEfficacy of therapeuticsQuantitative positron emission tomographyInsulin secretionDopamine receptorsD3 receptorsGlucose regulationPET radioligandEmission tomographyType 1Clinical usePET imagingReceptorsQuantitative PET imagingVMAT2Cellular transportersImagingVivoQuantitative imaging
2020
Reply: 11C-(+)-PHNO Trapping Reversibility for Quantitative PET Imaging of β-Cell Mass in Patients with Type 1 Diabetes
Bini J, Carson RE, Cline GW. Reply: 11C-(+)-PHNO Trapping Reversibility for Quantitative PET Imaging of β-Cell Mass in Patients with Type 1 Diabetes. Journal Of Nuclear Medicine 2020, 61: 1693-1693. PMID: 32620703, DOI: 10.2967/jnumed.120.250985.Peer-Reviewed Original ResearchMeSH KeywordsCarbon RadioisotopesDiabetes Mellitus, Type 1DopamineHumansPositron-Emission TomographyReceptors, Dopamine D3
2019
PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes
Bini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi N, Lim K, Najafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang Y, Herold K, Harris PE, Sherwin RS, Carson RE, Cline GW. PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes. Journal Of Nuclear Medicine 2019, 61: 570-576. PMID: 31601695, PMCID: PMC7198375, DOI: 10.2967/jnumed.119.234013.Peer-Reviewed Original ResearchConceptsT1DM individualsHealthy controlsDopamine DOutcome measuresAcute C-peptide responseSUVR-1Type 1 diabetes mellitusPET/CT scanningDuration of diabetesMaximal glycemic potentiationC-peptide responseClinical outcome measuresInsulin secretory capacityRoutine clinical measuresD3 receptor densityΒ-cell functionC-peptide releaseQuantitative PET measuresΒ-cell massDynamic PET scansQuantitative outcome measuresAgonist PET radioligandDiabetes mellitusReceptor agonistInsulin antibodies